loader2
Login Open ICICI 3-in-1 Account

TARSONS PRODUCTS LTD

IPO Details

ICICI Direct Research Rating : UNRATED
-
-
22 shares
-
₹ 635 – 662
₹ Upto 1023 cr

Timeline

  • 23-Nov-2021
  • 24-Nov-2021
  • 25-Nov-2021
  • 26-Nov-2021

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Tarsons Products Lts is a leading Indian life sciences company engaged in the designing, development, manufacturing and marketing of ‘consumables’, ‘reusables’ and ‘others’ including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations (“CROs”), Diagnostic companies and hospitals. They manufacture a range of quality labware products which helps advance scientific discovery and improve healthcare.

As of March 31, 2021, they had a diversified product portfolio with over 1,700 SKUs across 300 products.

Strengths & Risks

Strengths (3)

Comparison with Listed Industry Peers

There are no listed entities whose business portfolio is comparable with that of Tarsons Products business and comparable to their scale of operations.

Risks (3)

Failure to comply with quality standards may have an adverse effect on demand and on their reputation & business

They have emphasized on building strong quality management systems in their manufacturing processes as well as the raw materials used for manufacturing their products. Failure to maintain compliance with these quality standards may disrupt their ability to supply products which meet their end customers’ requirements.

Financials

Industry Overview

Indian Healthcare Industry Market
The Indian healthcare market has witnessed a growth of 9.1% in 2020 to reach ~USD 198 Bn. The Indian healthcare market is expected to register a huge growth of ~23% between 2020-2025 to reach ~USD 557 Bn by 2025 (Company DRHP; Frost & Sullivan).

Indian pharmaceutical companies - R&D spending
As per estimates, about USD 252 Bn worth of drug sales are likely to get off patent from 2020 to 2026. Some of the Indian companies are now well placed to capture this opportunity. With on-going developments, India has started focusing on selfreliance at a large scale.

India CRAMS Market (Contract Research and Manufacturing Services)
India is amongst the preferred destinations for outsourcing of research as well as manufacturing activities. New age CRAMS providers are able to cater to not just the pharmaceutical clients, but also biotech, agrochemicals, nutrition, animal health, consumer goods and others.

*The financials mentioned above are sourced from DRHP/ RHP documents.